Gemtesa (vibegron) works by activating a specific type of receptor on the bladder muscle, causing it to relax during filling and reducing the urgent, frequent need to urinate. It belongs to a class of medications called beta-3 agonists, and it’s taken as a once-daily 75 mg tablet to treat overactive bladder (OAB).
How Gemtesa Relaxes the Bladder
Your bladder wall is lined with smooth muscle that contracts when it’s time to urinate. During the filling phase, that muscle needs to stay relaxed so the bladder can expand and hold urine comfortably. This relaxation is controlled largely by beta-3 adrenergic receptors, which make up 94% to 97% of all the adrenaline-type receptors in bladder muscle tissue.
Gemtesa activates those beta-3 receptors, triggering the bladder muscle to relax. In overactive bladder, the muscle contracts too early or too often, creating urgency, frequent bathroom trips, and sometimes leakage. By keeping the muscle relaxed during filling, Gemtesa increases how much urine the bladder can hold before sending the “time to go” signal. The result is fewer trips to the bathroom and less urgency throughout the day.
Lab studies show that Gemtesa activates the beta-3 receptor more fully than mirabegron (Myrbetriq), the other drug in the same class. Relative to a reference compound, Gemtesa reached 99.2% of maximum receptor activation compared to 80.4% for mirabegron, and it did so at a lower concentration. In practice, though, clinical guidelines from the American Urological Association treat both medications as similarly effective for symptom relief.
How Much Improvement to Expect
In the 12-week EMPOWUR trial, people taking Gemtesa experienced measurable reductions across the main OAB symptoms compared to placebo:
- Daily bathroom trips: reduced by 1.8 per day (vs. 1.3 with placebo)
- Daily urgency incontinence episodes: reduced by 2.0 per day (vs. 1.4 with placebo)
- Daily urgency episodes: reduced by 2.7 per day (vs. 2.0 with placebo)
These differences may look modest on paper, but for someone who is urinating 10 or more times a day and dealing with sudden urges, cutting nearly two daily trips and almost three urgency episodes can meaningfully change how they move through the day. The improvements were even more pronounced in older adults. People 75 and older saw their daily urgency incontinence episodes drop by 2.0 with Gemtesa compared to just 0.4 with placebo, a gap that suggests the drug may be particularly beneficial in this age group.
How Quickly It Starts Working
Gemtesa begins working within days. In clinical trials, noticeable improvements in urgency, frequency, and incontinence appeared as early as two weeks, with the full benefit becoming statistically significant by 12 weeks. Most people won’t feel a dramatic overnight change, but a gradual reduction in bathroom trips and urgency over the first few weeks is typical.
Side Effects and Blood Pressure
The most common side effects (occurring in 2% or more of people in trials) are headache, urinary tract infection, common cold symptoms, diarrhea, and nausea. These side effects occurred at rates similar to placebo, meaning they weren’t much more common in people taking the drug than in those taking a sugar pill.
Blood pressure is where Gemtesa distinguishes itself from mirabegron. Mirabegron carries a prescribing warning about potential blood pressure increases, and periodic monitoring is recommended. Gemtesa does not carry that warning. In the 12-week pivotal trial, hypertension rates were identical between Gemtesa and placebo (1.7% in both groups). An ambulatory blood pressure monitoring study found that Gemtesa 75 mg had no significant effect on blood pressure or heart rate, including in people with pre-existing controlled hypertension. For people already managing high blood pressure, this difference can matter when choosing between the two beta-3 agonists.
Drug Interactions
The main interaction to know about is with digoxin, a heart medication. Gemtesa increases digoxin levels in the body by about 21% at peak concentration and 11% overall. If you take digoxin, your provider will likely monitor your digoxin levels before starting Gemtesa and periodically while you’re on it, as well as after stopping it.
Gemtesa does not significantly interfere with the major drug-processing pathways in the body at normal doses, which keeps its interaction profile relatively clean compared to some other bladder medications.
How It Compares to Older OAB Medications
Before beta-3 agonists, the standard OAB medications were antimuscarinics (also called anticholinergics). These drugs work by blocking the nerve signals that trigger bladder contractions, but they also block those same signals elsewhere in the body. That’s why they commonly cause dry mouth, constipation, blurred vision, and cognitive effects, particularly concerning in older adults where long-term anticholinergic use has been linked to increased dementia risk.
Gemtesa works through a completely different pathway. Instead of blocking nerve signals, it activates the relaxation receptors on the bladder muscle directly. This targeted approach avoids the anticholinergic side effects entirely. The AUA/SUFU guidelines now recommend beta-3 agonists alongside antimuscarinics as first-line drug therapy, with a strong recommendation backed by Grade A evidence. The guidelines note that no single medication has shown clear superiority over another in terms of efficacy, so the choice often comes down to side effect profile and individual response.
Taking Gemtesa
The standard dose is one 75 mg tablet taken once daily, with or without food. For people who have difficulty swallowing pills, the tablet can be crushed and mixed with about a tablespoon of applesauce, then taken immediately with a glass of water. Testing confirmed that crushing the tablet this way does not change how the drug is absorbed.